Telix Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLX research report →
Companytelixpharma.com
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma.
- CEO
- Christian Behrenbruch
- IPO
- 2024
- Employees
- 1,120
- HQ
- North Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $3.48B
- P/E
- -440.55
- P/S
- 3.91
- P/B
- 7.68
- EV/EBITDA
- 144.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 50.76%
- Op Margin
- 2.11%
- Net Margin
- -0.89%
- ROE
- -2.08%
- ROIC
- 1.77%
Growth & Income
- Revenue
- $1.21B · 53.91%
- Net Income
- $-10,685,154 · -121.40%
- EPS
- $-0.03 · -121.07%
- Op Income
- $26.64M
- FCF YoY
- -388.42%
Performance & Tape
- 52W High
- $18.49
- 52W Low
- $6.28
- 50D MA
- $9.84
- 200D MA
- $9.34
- Beta
- 0.65
- Avg Volume
- 235.09K
Get TickerSpark's AI analysis on TLX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | GILL DAVID N | other | 0 |
| May 11, 26 | Jellison William R | other | 0 |
| May 11, 26 | Rivas Maria | other | 0 |
| Apr 29, 26 | Behrenbruch Christian | buy | 33,435 |
| Apr 28, 26 | Behrenbruch Christian | buy | 34,500 |
| Mar 29, 26 | Smith Darren Charlton | other | 1,111 |
| Mar 29, 26 | Smith Darren Charlton | other | 1,111 |
| Mar 18, 26 | Cade David Norman | other | 0 |
| Mar 18, 26 | Cade David Norman | other | 78,189 |
| Mar 18, 26 | Cade David Norman | other | 84,293 |
Our TLX Coverage
We haven't published any research on TLX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate TLX Report →